Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced on January 6, 2025, the grant of 11,847 restricted stock units (RSUs) to a newly hired employee.
The RSUs will vest in four equal installments on each one-year anniversary of the grant date, provided the employee continues to serve with the company through each vesting date. This grant was made under the company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB), un'azienda focalizzata sullo sviluppo di medicinali genetici di precisione per malattie neuromuscolari e cardiache, ha annunciato il 6 gennaio 2025, l'assegnazione di 11.847 unit脿 azionarie riservate (RSU) a un nuovo dipendente assunto.
Le RSU matureranno in quattro rate uguali all'anniversario annuale della data di concessione, a condizione che il dipendente continui a lavorare per l'azienda fino a ciascuna data di maturazione. Questa concessione 猫 stata effettuata nell'ambito del Piano di Incentivazione Azionaria per il 2024 dell'azienda e rispetta la Regola di Quotazione Nasdaq 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB), una empresa enfocada en el desarrollo de medicamentos gen茅ticos precisos para enfermedades neuromusculares y card铆acas, anunci贸 el 6 de enero de 2025, la concesi贸n de 11,847 unidades de acciones restringidas (RSUs) a un nuevo empleado contratado.
Las RSUs se adquirir谩n en cuatro entregas iguales en cada aniversario de un a帽o de la fecha de concesi贸n, siempre que el empleado contin煤e trabajando con la empresa hasta cada fecha de adquisici贸n. Esta concesi贸n se realiz贸 bajo el Plan de Incentivos de Acciones de la empresa para 2024 y cumple con la Regla de Cotizaci贸n 5635(c)(4) de Nasdaq.
靻旊Μ霌� 氚旍澊鞓れ偓鞚挫柛鞀� (Nasdaq: SLDB)電� 鞁犼步攴检湣 氚� 鞁灔 歆堩櫂鞚� 鞙勴暅 鞝曤皜 鞙犾爠 鞚橂 臧滊皽鞐� 欷戩爯鞚� 霊愱碃 鞛堧姅 須岇偓搿�, 2025雲� 1鞗� 6鞚� 鞁犼窚 毂勳毄 歆侅洂鞐愱矊 11,847臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟.
RSU電� 攵�鞐澕鞚� 毵る厔 旮半厫鞚检棎 4須岇棎 瓯胳硱 霃欖澕頃� 牍勳湪搿� 歆�旮夒悩氅�, 歆侅洂鞚� 臧� 歆�旮夓澕鞐� 須岇偓鞐愳劀 瓿勳啀 攴茧頃橂姅 瓴届毎鞐� 頃措嫻霅╇媹雼�. 鞚� 攵�鞐姅 須岇偓鞚� 2024雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞙茧┌, Nasdaq 靸侅灔 攴滌爼 5635(c)(4)毳� 欷�靾橅暕雼堧嫟.
Solid Biosciences (Nasdaq: SLDB), une entreprise ax茅e sur le d茅veloppement de m茅dicaments g茅n茅tiques de pr茅cision pour les maladies neuromusculaires et cardiaques, a annonc茅 le 6 janvier 2025, l'octroi de 11 847 unit茅s d'actions restreintes (RSU) 脿 un nouvel employ茅 recrut茅.
Les RSU seront acquises en quatre versements 茅gaux 脿 chaque anniversaire de la date d'octroi, 脿 condition que l'employ茅 continue de travailler pour l'entreprise jusqu'脿 chaque date d'acquisition. Cet octroi a 茅t茅 fait dans le cadre du Plan d'Incentives en Actions 2024 de l'entreprise et est conforme 脿 la r猫gle de cotation Nasdaq 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen, das sich auf die Entwicklung pr盲ziser genetischer Therapeutika f眉r neuromuskul盲re und herzbezogene Erkrankungen konzentriert, gab am 6. Januar 2025 die Gew盲hrung von 11.847 nachrangigen Aktieneinheiten (RSUs) an einen neuangestellten Mitarbeiter bekannt.
Die RSUs werden in vier gleichen Tranchen am jeweils einj盲hrigen Jubil盲um des Gew盲hrungsdatums f盲llig, vorausgesetzt, der Mitarbeiter bleibt bis zu jedem Vesting-Datum im Unternehmen t盲tig. Diese Gew盲hrung wurde im Rahmen des Aktienanreizeplans 2024 des Unternehmens vorgenommen und entspricht der Nasdaq-Kotierungsregel 5635(c)(4).
- Grant of 11,847 RSUs to a new employee, potentially improving employee retention and motivation.
- The RSUs vest over four years, requiring the employee's continued service, which may pose a risk if the employee leaves before full vesting.
CHARLESTOWN, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.聽(Nasdaq: SLDB) (the 鈥淐ompany鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (鈥淩SUs鈥�) to one newly hired employee.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee鈥檚 continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company鈥檚 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee鈥檚 acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About聽Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid鈥檚 mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
What does the SLDB RSU grant mean for shareholders?
When will the SLDB RSUs vest?
What is the significance of Nasdaq Listing Rule 5635(c)(4) in SLDB's grant?
How many RSUs did SLDB grant to the new employee?
What is the purpose of SLDB's 2024 Inducement Stock Incentive Plan?
